- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe Crohn disease; complex refractory fistulising Crohn disease; moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; adult patients with a history of jovenile idiopathic arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; severe active rheumatoid arthritis
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 804KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 46KB)
Adalimumab – November 2020
Adalimumab: Injection 40 mg in 0.8 mL pre-filled syringe, Injection 40 mg in 0.8 mL single dose autoinjector; Hadlima®
Last updated
19 March 2021